Table 2.
Demographics of IgG Seropositive and Seronegative Adults With Glioma, San Francisco Bay Area Adult Glioma Study
| VZV | EBV | HSV | CMV | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| + | - | P | + | - | P | + | - | P | + | - | P | |
| No. | 1296 | 78 | 723 | 58 | 564 | 211 | 428 | 353 | ||||
| Mean age | 50.8 | 50.9 | .95 | 50.6 | 50.2 | .72 | 52.5 | 45.5 | <.001 | 52.5 | 48.4 | <.001 |
| Median mo. survival | 25.7 | 18.8 | .16 | 22.5 | 17.8 | .79 | 20.0 | 31.4 | .002 | 20.0 | 25.3 | .07 |
| % white | 87.4% | 78.2% | .03 | 87.4% | 89.7% | .77 | 87.2% | 88.2% | .82 | 82.5% | 93.8% | <.001 |
| % on Dexamethasone | 33.9% | 38.5% | .53 | 26.2% | 37.9% | .91 | 36.0% | 37.4% | .61 | 35.7% | 37.1% | .64 |
| % grade IV | 55.2% | 60.3% | .28 | 53.8% | 46.6% | .48 | 56.0% | 46.0% | .03 | 54.0% | 52.4% | .58 |
| % IDH mutated | 30.1% | 29.5% | .99 | 32.0% | 31.9% | .99 | 30.2% | 37.4% | .10 | 29.6% | 35.0% | .16 |
+ = seropositive, − =seronegative, P = P-value for difference between seropositive and seronegative.
Chi-square tests were used by default to test categorical variables. Age differences were assessed using a Wilcoxon rank sum test. Univariate analysis of survival differences was assessed using a log-rank test.